Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial
Clare Stirzaker, Ulrike Nitz, Eva‐Maria Grischke, Oleg Gluz et al.
Citations
6 citations
Journal
Molecular Cancer
Topics
Breast Cancer Treatment Studies
Field-Weighted Citation Impact (FWCI)
5.62
article
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial
Clare Stirzaker, Ulrike Nitz, Eva‐Maria Grischke, Oleg Gluz, Matthias Christgen, Christoph Uleer, Nadia Harbeck, Bahriye Aktas, Rachel Wuerstlein, Monika Graeser, Christine zu Eulenburg, Susan J. Clark, Hans Heinrich Kreipe, Matt Trau, Darren Korbie, Michael Braun, Sherko Küemmel, Mathias Warm, Helmut Forstbauer, Enrico Pelz, John Hackmann, Claudia Schumacher
article en
6 citations
Abstract
No abstract available for this paper.
Publication Tag
Molecular CancerVol. 24(1)
Institutions
Garvan Institute of Medical Research (AU), University of Hildesheim (DE), Universität Hamburg (DE), The University of Queensland (AU), Deutsches Archäologisches Institut, Zentrale (DE), Medizinische Hochschule Hannover (DE), University Medical Center Hamburg-Eppendorf (DE), Essen University Hospital (DE), St Vincent's Clinic (AU), University Hospital Leipzig (DE), Marien Hospital Witten (DE), Kliniken Essen-Mitte (DE), Rotkreuzklinikum München (DE), LVR-Klinik für Orthopädie Viersen (DE), Atos Medical (DE), Krankenhaus Köln-Holweide (DE), Ludwig-Maximilians-Universität München (DE)
Funders
National Breast Cancer Foundation, National Health and Medical Research Council